What is the tomy s program?

Transcription

1 What is the tmy s prgram? The tmy s prgram tmy s (Teva s Orphan hematlgical Malignancies award fr Yung hematlgists and researchers) is an educatinal award prgram fr yung hematlgists/researchers, rganized by Teva Onclgy Each year, the tmy s prgram will recgnize yung hematlgists/researchers wh can illustrate the latest scientific advances in the management f rphan hematlgical malignancies by presenting their research in a didactic and engaging manner, demnstrating their excellence in educatin and presentatin skills The first award was presented during a Teva-rganized sympsium at ACUTE LEUKEMIAS XVI in Munich, Germany, in February 2017 The final presentatins fr the secnd tmy s award will take place during a Teva-rganized sessin at the 7 th Internatinal Sympsium n Acute Prmyelcytic Leukemia, which will be held in Rme, Italy, frm September 24 t 27, 2017 Why is Teva Onclgy rganizing this initiative? Teva Onclgy is cmmitted t encuraging yung hematlgists/researchers in the study f rphan hematlgical malignancies, and t wrking tgether twards the gal f understanding the pathphysilgy and imprving diagnsis and management f these rare hematlgical cancers. Wh is n the tmy s jury? The fllwing experts in rphan hematlgical malignancies are all members f the 2017 tmy s jury: Pierre Fenaux, France Francesc L-Cc, Italy Bb Löwenberg, Netherlands Nigel Russell, UK Miguel Sanz, Spain Richard Schlenk, Germany

2 In subsequent years, the jury may feature ther experts in the field f rphan hematlgical malignancies. What will the tmy s finalists and winner receive? The authrs f the best abstracts (a maximum f 8) will be awarded travel and accmmdatin csts and registratin fees t attend a Eurpean hematlgical cngress; fr the secnd tmy s award prgram this will be the 7 th Internatinal Sympsium n Acute Prmyelcytic Leukemia in Rme, Italy, frm September 24 t 27, The authrs f the tp 4 abstracts will receive editrial supprt t develp an ral presentatin t be given at a Teva-rganized sessin during the main sympsium. The best presenter, judged bth n cntent and presentatin skills, will be chsen as the tmy s winner; he r she will be awarded the tmy s trphy, as well as travel and accmmdatin csts and registratin fees fr the American Sciety f Hematlgy (ASH) Annual Meeting and Expsitin in Atlanta, GA, USA, in December The authrs f the 4 next best abstracts will receive editrial, typesetting, and printing supprt t develp a pster t be presented at the main sympsium. Call fr Abstracts - The secnd tmy s award 2017 General requirements and eligibility The first authr shuld be a yung hematlgist/researcher, a physician training t becme a hematlgist, a PhD student r a PhD-level scientist; they shuld be aged 40 years r yunger at the deadline fr abstract submissin Eligibility includes first authrs affiliated t an institutin in any cuntry except the USA The abstract shuld reprt n ne f the tpics listed in the details fr submissins t the 7 th Internatinal Sympsium n Acute Prmyelcytic Leukemia (fr mre infrmatin see Abstract frmat

3 The abstract frmat shuld fllw the guidelines fr the 7 th Internatinal Sympsium n Acute Prmyelcytic Leukemia Abstract submissin dates Abstracts can be submitted frm March via the sympsium website: The deadline fr abstract submissin is PM (Pacific Daylight Time) n May 31, 2017 Respnsibilities f the first authr The first authr listed fr each abstract serves as the presenting authr and as the primary cntact fr all tmy s crrespndence, unless therwise indicated in the Cmments sectin f the nline abstract submissin frm The first authr is respnsible fr: Ensuring that all authrs have read the abstract and have agreed t be c-authrs Obtaining all cnflict-f-interest disclsure and cpyright transfer infrmatin frm c-authrs Waiving any and all claims against Excerpta Medica and Teva Onclgy and any reviewer arising frm r relating t the abstract submissin and review prcess, including but nt limited t peer review and abstract evaluatin

4 Additinal infrmatin During the disclsure submissin prcess yu will als be required t indicate yur cmpliance with the fllwing: If yu are prviding recmmendatins invlving clinical medicine, these recmmendatins will be based n evidence that is accepted within the medical prfessin as adequate justificatin fr indicatin and cntraindicatins f these medicines in patients care; all scientific research referred t in supprt f a patient-care recmmendatin will cnfrm t generally accepted standards f experimental design, data cllectin, and analysis The cntent f the infrmatin with which yu are invlved will prmte quality in health care r advances in science, and will nt prmte a specific prprietary r cmmercial interest; cntent fr this publicatin will be well-balanced and unbiased If yu have been trained r used by a cmmercial entity r its agents as a speaker (e.g. via participatin in a speakers bureau) fr any cmmercial interest, the prmtinal aspects f that wrk must nt be included in the presentatin in any way Abstract review and selectin After the abstract deadline, all eligible abstracts will be made available t the jury fr blinded review and scring The scre assigned by a jury member t an abstract submitted by an authr frm the same institutin as the jury member will be disregarded Abstracts will be evaluated based n: Scientific merit f the clinical case Bilgical/clinical impact The jury will select the best abstracts (maximum f 8), irrespective f the categry, based n the abve criteria. The tp 4 abstracts will be presented as ral presentatins at a Teva-rganized sessin during the 7 th Internatinal Sympsium n Acute Prmyelcytic Leukemia in Rme, Italy, frm September 24 t The remaining 4 abstracts will be develped as psters t be displayed in the Teva bth at the main sympsium

5 Oral presenters will be asked t submit slides (a maximum f 10) t Excerpta Medica by September 1, 2017; Excerpta Medica will prvide editrial supprt fr the presentatin The pster presenters will receive typesetting and editrial supprt frm Excerpta Medica; the cntent f the pster shuld be fully defined by the authr in accrdance with guidelines that will be prvided, and shuld be submitted t Excerpta Medica by September 1, 2017, t allw sufficient time fr preparatin Excerpta Medica will cntact the authrs f abstracts selected fr pster and/r ral presentatins t make travel and accmmdatin arrangements Acceptance/rejectin ntificatin Ntificatin regarding acceptance r rejectin f abstracts will be sent by t the presenting authr befre July 15, 2017; it is, therefre, vital that yu prvide the crrect address with yur abstract submissin If an abstract is accepted, the will specify whether it has been selected as an ral r pster presentatin Abstract withdrawal Once an abstract is selected, the presenter cmmits t attending the meeting Further use f the abstracts All selected abstracts will be published in an abstract bk that will be made available t sympsium attendees Teva Onclgy reserves the right t use the case studies/case series in ther educatinal and prmtinal materials Cntact infrmatin Fr queries regarding abstract submissins r ntificatins, please cntact: supprt@nctmys.cm HQ/ONCO/16/0142e